Home » Invokana » Invokana Lawsuit

Invokana Lawsuit

• More on Invokana
  • Invokana Class Action
  • Invokamet
  • Invokana Heart Attack
  • Invokana Kidney Failure
  • Invokana Diabetic Ketoacidosis
  • Invokamet Lawsuit
  • Invokana Ketoacidosis
  • Invokana Lawsuit

Invokana and other SGLT2 inhibitors used to treat Type 2 diabetes have come under scrutiny due to a possible link with diabetic ketoacidosis. These concerns could lead to a wave of Invokana lawsuits and other product liability claims against the pharmaceutical companies that market this class of medications. If you were diagnosed with this dangerous condition while using Invokana or any other SGLT2 inhibitor, it’s important to seek legal advice as soon as possible in order to ensure that your rights are protected. To learn more, please callto arrange for a private, no-obligation review of your case with an attorney at Bernstein Liebhard LLP.

Invokana Lawsuit Developments

• January 2017: An Order issued this month indicates thatthe  federal Invokana litigation will  conduct concurrent discovery and mediation. The parties have been directed to meet and confer on the appointment of a special master/mediator to preside over those aspects of the litigation. Read More
• December 2016: An Order issued in the U.S. District Court, District of New Jersey, indicates that the federal Invokana litigation will convene its first Case Management Conference on January 12, 2017 at 10:30 a.m. Read More
• December 2016: The U.S. Judicial Panel on Multidistrict Litigation (JPML) has centralized all federally-filed Invokana lawsuits in the U.S. District Court, District of New Jersey. The new multidistrict litigation includes 55 lawsuits, all filed on behalf of individuals who allegedly suffered diabetic ketoacidosis, kidney damage and other side effects related to their use of Invokana. Any future federal filings will also be eligible for transfer to New Jersey.  However, the proceeding will not include product liability claims involving other Type 2 diabetes drugs in the SGLT-2 inhibitor class. Read More
• October  2016: The U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear Oral Arguments on a Motion to Transfer all federally-filed Invokana lawsuits to a single U.S. District Court for the purposes of  coordinated pretrial proceedings during its next Hearing Session. That Session is scheduled for December 1^st in Charlotte, North Carolina. Read More
• September 2016: Invokana lawsuit plaintiffs in Philadelphia, Pennsylvania have filed a petition seeking mass tort status for their claims. According to the September 23rd filing, 87 cases involving allegations of ketoacidosis and kidney failure are already pending in the Philadelphia Court of Common Pleas, and plaintiffs assert that the number of filings could double. Read More
• September 2016: A motion filed with the JPML on September 21st seeks  to have all federally-filed Invokana lawsuits alleging ketoacidosis, kidney injury and heart attacks centralized in a single federal court. The motion notes that 56 such cases are already pending in 11 jurisdictions, and suggest that the U.S. District Court, District of New Jersey, would be an appropriate venue for the proposed multidistrict litigation. Read More
• August 2016: An Invokana lawsuit has been filed in Kentucky federal court by a plaintiff who claims that the Type 2 diabetes drug was responsible for a heart attack he suffered in July 2015. The lawsuit, which appears to be one of the first to put forth heart attack allegations, asserts that the drug’s manufacturers  misrepresented it as a safe and effective treatment for  diabetes, and alleges that  Invokana causes serious medical problems, such as diabetic ketoacidosis, kidney failure, and cardiovascular problems. Read More
• July 2016: Another Invokana lawsuit is filed on behalf of a ketoacidosis victim, this time in New  Jersey federal court. the complaint claims that the drug’s manufacturers were aware that Invokana could cause this dangerous complication, but placed profits ahead of patient safety and failed to issue adequate warnings to the public and medical community. Read More
• July 2016: A wrongful death lawsuit has been filed on behalf of an Invokana user who suffered from diabetic ketoacidosis, heart problems, kidney damage, stroke, and eventual death, allegedly related to her use of the Type 2 diabetes medication. The complaint claims that Johnson & Johnson and its Janssen Pharmaceuticals unit knew or should have known about the risks associated with Invokana, yet withheld this critical information from patients and doctors. Read More
• April 2016:  More than 150 Invokana lawsuits have been filed in federal and state courts, including at least 15 that are pending in Pennsylvania’s Philadelphia Court of Common Pleas. Dozens have also been filed in Missouri and Illinois state courts, while several cases are pending in the U.S. District Court, District of New Jersey. All were brought on behalf of patients who allegedly suffered ketoacidosis or kidney damage due to their use of Invokana.  Read More
• March 2016: Two Invokana lawsuits filed in New Jersey federal court claim that the medication is associated with an increased risk of kidney damage. One of the cases involves the alleged wrongful death of a man who died as a result of kidney complications just two months after he was prescribed Invokana. Read More
• March 2016: A Texas woman is seeking $10 million for ketoacidosis and kidney damage that allegedly resulted from her use of Invokana. She claims that Johnson & Johnson and its Janssen subsidiary are responsible for her injuries, as she relied on materials provided by the defendants that represented Invokana as a safe and effective medication. Read More
• November 2015: A California woman has filed Invokana lawsuit alleging that Johnson & Johnson and its Janssen Pharmaceuticals unit failed to adequately warn physicians about the risks associated with the medication.
• October 2015: An class action lawsuit is filed in Canada that seeks more than $1 billion in damages on behalf of Invokana patients in that country who were allegedly harmed by the drug. Read More

FDA Diabetic Ketoacidosis Safety Review of SGLT2 Inhibitors

In May 2015, the U.S. Food & Drug Administration (FDA) began to review Invokana and other SGLT2 inhibitors after receiving at least 20 reports of diabetic ketoacidosis that had occurred in patients taking the drugs. In addition to Invokana, other Type 2 diabetes medications subject to the FDA’s review included:

• Invokamet (canagliflozin and metformin)
• Farxiga (dapagliflozin)
• Xigduo XR (dapagliflozin and metformin extended-release)
• Jardiance (empagliflozin)
• Glyxambi (empagliflozin and linagliptin)

Also known as ketoacidosis, ketosis or acidosis, diabetic ketoacidosis is a potentially fatal condition that results from the build up of toxic acids in the blood known as ketones. Affected patients may experience difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness. Invokana patients should contact their doctor immediately if they develop any of these symptoms, as this condition can quickly lead to diabetic coma and death.

FDA Orders New Diabetic Ketoacidosis Warnings for SGLT2 Inhibitors

In December 2015, the  FDA orderd the manufacturers of Invokana and other SGLT2 inhibitors to modify the drugs’ labels by adding new warnings to their product labels regarding a potential association with ketoacidosis and serious urinary tract infections, both of which may lead to hospitalization. According to the agency,  the review initiated in May 2015 revealed at least 73 cases of ketoacidosis that had been reported to the FDA’s adverse event database from March 2013 to May 2015.

The database also received 19 reports of life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that started as urinary tract infections among SGLT2 inhibitor patients from March 2013 through October 2014. All 19 patients were hospitalized, and some required treatment for kidney failure. Read More

European Regulator Issues New SGLT2 Recommendations

On February 12, 2016, the European Medicines Agency (EMA) recommended  that individuals using SGLT2 inhibitors immediately contact their doctor if they experience symptoms indicative of ketoacidosis. The regulator also advised doctors to immediately cease SGLT2 inhibitor treatment in patients who present with such symptoms until the cause is identified and treated. Read More

Invokana Label Change Prompted by Acute Kidney Injury Reports

The FDA disclosed that  Invokana, Invokamet, Farxiga and Xiduo XR had been named in  101 cases of acute kidney injury logged with its database between March 29, 2013, to October 19, 2015.  73 of those involved canagliflozin, the active ingredient in Invokana and Invokamet. The labels for all four medications were updated to reflect this potential risk. Read More

Invokana and Amputations

The EMA announced it was reviewing Invokana for a possible link to lower-limb amputations, after a large ongoing clinical trial showed an increase in toe amputations among patients taking canagliflozin. The probe could eventually include other SGLT2 inhibitor drugs. Read More

In April 2016, the FDA also announced that it was investigating a possible link between foot and leg amputations possibly related to the use of Invokana. Read More

Filing an Invokana Lawsuit

You may be entitled to file an Invokana lawsuit if you or a loved one were diagnosed with ketoacidosis while using this medication to treat Type 2 diabetes. Janssen and other companies that market SGLT2 inhibitors could be liable for failure to warn, negligence, manufacturing and design defects, and misrepresentation if it is found that their products cause ketoacidosis. Successful Invokana plaintiffs may be able to recover damages for lost wages, medical bills, pain and suffering, and even wrongful death.

If you are considering filing an Invokana ketoacidosis lawsuit, you may be concerned about the legal costs you could incur. Fortunately, you don’t need to worry, as Bernstein Liebhard LLP represents clients in drug injury cases on a contingency basis. This means that you will only pay legal costs and attorneys’ fees if we are able to obtain a settlement or judgment on your behalf. In such cases, your legal fees would be taken from portion of your recovery, which is detailed in the retainer agreement you sign with our Firm. If your Invokana case does not reach a successful conclusion, you will owe nothing.

Our attorneys are available right now to evaluate your potential Invokana lawsuit, and can determine whether or not you have a valid claim. If you or a loved one were diagnosed with diabetic ketoacidosis while using Invokana or another SGLT2 inhibitor to treat Type 2 diabetes, please callto speak with an attorney today.